| Literature DB >> 35355907 |
Balaji Ramanathan1, Jeyasudha Murugan1, Kumaravel Velayutham1.
Abstract
Background: Polycystic ovarian syndrome (PCOS) is typically characterized by a spectrum of manifestations that include menstrual irregularities, anovulation, cysts, hyperandrogenic features like hirsutism, acne, alopecia, and various metabolic complications. The pathology of PCOS is complex and several mechanisms have been potentially involved in the genetic abnormalities/dysfunctions. Hence, the present study aims to examine the prevalence and association of polymorphisms in candidate genes (thyroid adenoma-associated gene [THADA], luteinizing hormone and human chorionic gonadotropin receptor [LHCGR], DENN domain containing 1A [DENND1A], follicle-stimulating hormone receptor [FSHR], Connexin37 [CX37], angiotensin-converting enzyme [ACE], insulin receptor [INSR] and calpain 10 [CAPN10]) in PCOS patients of the South Indian regional population.Entities:
Keywords: ACE; CAPN10; CX37; DENND1A; FSHR; INSR; LHCGR; PCR; RFLP; THADA; polycystic ovarian syndrome; polymorphism
Year: 2022 PMID: 35355907 PMCID: PMC8959196 DOI: 10.4103/ijem.ijem_340_21
Source DB: PubMed Journal: Indian J Endocrinol Metab ISSN: 2230-9500
Figure 1Pathophysiology of PCOS susceptible gene markers.
Baseline characteristics of the control and PCOS women
| Parameter | Control ( | Patients ( |
|---|---|---|
| Age (years) | 26.9±6.34 | 26.9±5.46 |
| BMI (kg/m2) | 23.4±4.7 | 30.4±6.4** |
| RBS (mg/dL) | 107.1±11.9 | 109.5±41.3 |
| T.CHO (mg/dL) | 159.5±31.65 | 175.7±29.8 |
| TGL (mg/dL) | 109.28±25.2 | 205.9±77.6** |
| HDL (mg/dL) | 33.9±7.48 | 41.4±11.4 |
| LDL (mg/dL) | 83.57±8.26 | 92.7±26.4 |
| TSH (mIU/mL) | 2.96±0.955 | 4.2±3.8 |
| FT4 (ng/dL) | 1.1±0.321 | 1.2±0.4 |
| LH (mIU/mL) | 7.25±1.9 | 11.0±7.0 |
| FSH (mIU/mL) | 4.9±1.74 | 5.8±1.8 |
| Prolactin (ng/mL) | 10.7±3.07 | 15.2±7.6 |
| E2 (pg/mL) | 88±15.8 | 80.1±48.1 |
| DHEAS (µg/dL) | 185.8±63.3 | 266±128.9* |
Values are mean±SD of triplicate experiments. *Significant at P<0.05, ** significant at P<0.01. BMI-Body mass index; RBS-Random blood sugar, T.CHO-Total cholesterol; TGL-Triglyceride levels; HDL-High density lipid; LDL-Low density lipid; TSH-Thyroid stimulating hormone; FT4-Thyroxine; LH-Luteinizing hormone; FSH - Follicle-stimulating hormone; E2-Estradiol; DHEAS - Dehydroepiandrosterone sulfate
Genotypic and allelic frequencies of PCOS susceptible gene polymorphisms
| Cases | Control | HWE | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
| |||||||||
| Genotype % ( | Allele % | Genotype % ( | Allele % | |||||||
| DENND1A (rs10818854) | GG | 90 (18) | G | 95 | GG | 100 (10) | G | 100 | 13.76 (0.001*) | 2.065 (0.356) |
| GA+AA | 10 (2) | A | 5 | GA+GG | 0 (0) | A | 0 | |||
| LHCGR (rs13405728) | AA | 50 (10) | A | 75 | AA | 50 (5) | A | 75 | 1.667 (0.197) | 2.297 (0.130) |
| AG+GG | 50 (10) | G | 25 | AG+GG | 50 (5) | G | 25 | |||
| THADA (rs13429458) | AA | 80 (16) | A | 90 | AA | 80 (8) | A | 85 | 1.071 (0.301) | 1.154 (0.183) |
| AC+CC | 20 (4) | C | 10 | AC+CC | 20 (2) | C | 15 | |||
| FSHR (rs2349415) | AA | 10 (2) | A | 40 | AA | 0 (0) | A | 15 | 2.857 (0.091) | 11.627 (0.001*) |
| AG+GG | 90 (18) | G | 60 | AG+GG | 100 (10) | G | 85 | |||
| CX37 (rs1764391) | CC | 70 (14) | C | 82.5 | CC | 50 (5) | C | 70 | 2.500 (0.114) | 8.64 (0.003*) |
| CG+GG | 30 (6) | G | 17.5 | CG+GG | 50 (5) | G | 30 | |||
| ACEI/D (rs1799752) | II | 30 (6) | I | 57.5 | II | 10 (1) | I | 25 | 3.333 (0.504) | 1.568 (0.457) |
| ID | 55 (11) | D | 42.5 | ID | 30 (3) | D | 75 | |||
| DD | 15 (3) | DD | 60 (6) | |||||||
| INSR (rs1799817) | CC | 45 (9) | C | 70 | CC | 20 (2) | C | 45 | 2.222 (0.329) | 12.150 (0.001*) |
| CT+TT | 55 (11) | T | 30 | CT+TT | 80 (8) | T | 55 | |||
| CAPN10 (rs2975760) | TT | 65 (13) | T | 82.5 | TT | 80 (8) | T | 90 | 1.071 (0.301) | 1.875 (0.171) |
| TC+CC | 35 (7) | C | 17.5 | TC+CC | 20 (2) | C | 10 | |||
*Significant at P<0.05; χ2: Pearson’s Chi-square test to assess the relative association between the patients and controls for genotype and allele frequencies; HWE χ2 indicates the result from the Hardy-Weinberg distribution of genotypes in the PCOS and control groups; DENND1A - DENN domain containing 1A; LHCGR - Luteinizing hormone/chorionic gonadotropin receptor. FSHR - follicle-stimulating hormone receptor; CX37 - Connexin37; ACE I/D - Angiotensin-converting enzyme insertion/deletion polymorphism; INSR - Insulin receptor; CAPN10 - Calpain-10
Figure 2Determination of the incidence of the studied SNPs in controls and PCOS patients (a) Separation of PCR product encompasses SNP, electrophoretically in a 2% agarose gel (b) Chromatographs show the variants of study genes (c) RFLP analysis (i) rs2349415 SNP of FSHR with BspPI enzyme (ii) rs2975760 SNP of CAPN10 with Fnu4HI enzyme (d) Analysis of the insertion/deletion polymorphism of the ACE gene.